Overview of Alprostadil

Alprostadil is a prescription medication utilized to manage medical conditions that require the augmentation of localized blood flow, such as improving circulation in certain tissues or maintaining specific vascular patency.

Property	Description
Active ingredient	Alprostadil (INN)
Form	Intracavernosal solution, intraurethral suppository, intravenous infusion
Pharmacological class	Prostaglandin E₁ Agonist and Vasodilator
Origin	Synthetic analog of Prostaglandin E₁ (PGE₁)

Classification and Nature: Prostaglandin E₁ Agonist

Alprostadil is the active ingredient (INN) classified pharmacologically as a potent Prostaglandin E₁ Agonist and a direct Vasodilator. This means the medicine acts directly to widen blood vessels, which is its fundamental mechanism. The active compound is a synthetic analog of the naturally occurring lipid Prostaglandin E₁ (PGE₁), a key regulator in biological processes like smooth muscle and vascular function. Unlike indirect treatments, Alprostadil provides a focused, high-impact vascular response by mimicking the body's natural signaling molecules, a capability clinically recognized for its direct action on the vasculature.

Pharmaceutical Identity and Delivery

The drug is prepared in specialized dosage forms to ensure highly targeted or critical systemic delivery. These forms include a powder for solution for intracavernosal injection, a minute intraurethral suppository (pellet), and a solution for intravenous infusion. These distinct preparations allow the medicine to be administered either locally, concentrating the powerful vasodilator effect where it is needed, or systemically for critical care applications. This distinction in administration routes (local vs. systemic) is a differentiating factor compared to many orally administered vascular treatments, enabling its use in specific, localized scenarios or to manage critical circulatory needs in newborns.

General Purpose of Action

The essential purpose of Alprostadil is to achieve substantial smooth muscle relaxation and localized vasodilation, leading to a necessary increase in blood perfusion to a specific area of the body. This effect is initiated by raising intracellular cyclic adenosine monophosphate (cAMP) levels. This profound circulatory change provides a reliable mechanism for promoting adequate blood engorgement in localized structures or for maintaining the necessary patency of critical vascular channels, fulfilling a key requirement for targeted therapeutic interventions.

Regulatory References

NIH MedlinePlus Drug Information on Alprostadil

What side effects are possible with Alprostadil?

Possible Side Effects and Safety Information

The safety profile of Alprostadil is strictly defined by regulatory documents, which categorize adverse reactions based on frequency and the route of administration, reflecting the drug's potent vasodilator action.

Adverse events associated with localized use (intracavernosal or intraurethral) are frequently classified as local reactions. The most commonly documented reaction is Penile Pain, which is often classified as a Very Common event (occurring in ge 1/10 patients). Other effects classified as Common include injection site haematoma and ecchymosis, along with systemic effects such as headache and dizziness [FDA Label].

Specific risks recognized as serious in regulatory documents include Priapism (a prolonged erection lasting four hours or more) and the development of Penile Fibrosis (structural changes such as Peyronie's disease or cavernosal fibrosis). Penile Fibrosis is noted to be associated with long-term use and requires routine physical examination [EMA SmPC].

For the intravenous administration route, primarily used in neonates, the safety profile emphasizes systemic risk. Apnea (temporary cessation of breathing) is a serious concern, often reported to occur during the first hour of infusion, especially in low-birth-weight infants. Due to the drug's powerful systemic effects, continuous monitoring of arterial pressure is mandated in this critical care setting [FDA Label, Prostin VR Pediatric]. Safety constraints further limit use in patients with pre-existing anatomical penile deformation or conditions that predispose them to Priapism, as explicitly defined in regulatory prescribing information.

This official safety information structures the understanding of the medicine's risks by clearly documenting the critical local and systemic events across the different dosage forms.

Overdose and Emergency Response

The official regulatory documentation for Alprostadil defines overdose manifestations and the required emergency actions based on the administration route.

For localized use (intracavernosal or intraurethral), the most significant manifestation of overdose is a prolonged erection or priapism (an erection lasting longer than six hours). Regulatory authorities mandate that individuals must seek immediate medical assistance for any erection that persists for longer than four hours. This explicit instruction is required because untreated priapism carries a documented risk of severe, irreversible penile tissue damage and permanent loss of potency. Systemic effects, such as hypotension, dizziness, or fainting, may also occur and necessitate medical supervision until resolution.

In the context of intravenous infusion, typically used in neonates, documented overdose presentations include cardiorespiratory effects such as apnea (temporary stopping of breathing), bradycardia (slow heartbeat), and hypotension. Apnea is noted in the regulatory labeling as most often occurring in neonates weighing less than 2 kg. In these scenarios, regulatory guidance requires the immediate discontinuation of the infusion and the provision of appropriate medical treatment. Management in overdose situations focuses on symptomatic and supportive care, consistent with official regulatory instructions.

Therapeutic Uses of Alprostadil

What Alprostadil Treats: Main Uses and Therapeutic Benefits

Alprostadil is relevant across acute therapeutic contexts. Its applications focus on providing supportive relief in situations involving certain distressing symptoms and acute physiological stress. It is commonly used across conditions characterized by episodic or fluctuating symptom patterns, including erectile dysfunction (impotence) and acute heart-related conditions in specific newborn infants.

Symptomatic Relief for Erectile Dysfunction (ED)

Alprostadil is relevant for managing the symptoms of erectile dysfunction in adult males. It is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that interfere with daily comfort. It is commonly used when short-term symptomatic assistance is needed, providing supportive relief when symptoms interfere with routine sexual activities. This supports the patient during difficult episodes by easing distress.

The medication is applied in contexts where additional symptomatic support is needed.

Supportive Management in Neonatal Heart Conditions

In a distinct clinical context, Alprostadil is relevant in conditions associated with acute or disruptive episodes in specific newborn infants. It is applied in clinical settings that involve acute or unstable symptom patterns where temporary support is appropriate. It is commonly used when short-term symptomatic assistance is needed, applying across domains where additional symptomatic support is needed. This use is relevant for easing symptoms that create noticeable physiological strain during difficult episodes.

Quick Fact: Symptom Focus (Is applied in contexts where additional management of discomfort is required.)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Alprostadil — official regulatory information

Eligibility Scope

Classification	Approved/Contraindicated Populations (Label-Based)
Populations Allowed	Adult Males (for erectile dysfunction forms) and Neonates/Infants (for temporary maintenance of ductus arteriosus patency)
Contraindicated Groups	Men with penile implants, anatomical penile deformation (e.g., Peyronie’s disease), or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Non-Indicated Groups	Women and most Children (intracavernosal/urethral forms are not for use)

Age and Condition-Specific Rules

Neonates with Respiratory Distress Syndrome are contraindicated for the intravenous form. Those weighing less than 2 kg require close monitoring due to the increased risk of apnea.
Older Adults are an eligible population; however, caution is recommended in the presence of age-related kidney issues, which may affect drug clearance.
The drug is contraindicated in any patient with a known hypersensitivity to Alprostadil or its excipients.
Conditional use is specified for patients with cardiovascular risk factors and for neonates with bleeding tendencies (due to antiplatelet effects).

Pregnancy and Lactation Eligibility Status

Alprostadil is not indicated for use in female patients and is not approved for use during pregnancy or breastfeeding. Male patients whose partner is pregnant or of childbearing potential are advised in the labeling to use a barrier method (condom) during intercourse to prevent fetal exposure to the drug via seminal fluid.

Connection to the overall eligibility profile

Official regulatory documents define Alprostadil’s use across two highly distinct patient groups: adult males and a specific subset of critically ill neonates. This specialized usage necessitates absolute contraindications against men with pre-existing conditions that increase the risk of prolonged erection or patients with specific heart conditions. Eligibility is therefore strictly constrained by the patient's age, gender, and underlying clinical status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe the interaction profile of Alprostadil primarily through pharmacodynamic mechanisms related to its potent vasodilatory and anti-platelet effects, with little to no formal documentation of pharmacokinetic interactions due to rapid local metabolism.

Interaction Classifications

Interaction Entity	Regulatory Classification	Documented Interaction Outcome
Other Agents for Erectile Dysfunction (e.g., PDE5 inhibitors)	Contraindicated / Prohibited	Co-administration is prohibited due to the potential for additive effects and the unknown risk of increased cardiovascular strain.
Other Vasoactive Agents (e.g., papaverine, phentolamine)	Not Recommended	Use of combinations is not recommended, as their safety and efficacy have not been systematically evaluated.
Anticoagulants (e.g., Warfarin, Heparin)	Use with Caution	Increased propensity for bleeding and localized injection site bleeding is possible due to Alprostadil’s platelet aggregation inhibitory effect.
Antihypertensive Drugs	Use with Caution	Combination may enhance the hypotensive effect, leading to an increased risk of low blood pressure.

Interaction with alcohol (contained in beverages) is documented as potentially decreasing the effectiveness of the medication. Elderly patients who are concomitantly receiving antihypertensive or other vasoactive medications have a specifically noted increased risk for hypotension.

Mechanism of Action

Receptor-Mediated Smooth Muscle Relaxation

Alprostadil, a synthetic analog of prostaglandin E1, functions as an agonist by binding to E prostanoid receptors, primarily subtypes EP2 and EP4, located on vascular smooth muscle cells. This binding triggers the activation of the coupled stimulatory G-protein ( G s) pathway, initiating the molecular cascade that modulates the contractile state of the vessel walls.

The cAMP Signaling Cascade and Vascular Tone

Activation of G s stimulates the enzyme adenylyl cyclase, which catalyzes the formation of the second messenger, cyclic AMP ( cAMP) . Elevated cAMP activates PKA, leading to a functional decrease in the effective intracellular concentration of calcium ions ( Ca^2+) by enhancing its sequestration. This molecular shift inhibits the contractile proteins, resulting in the lowering of vascular tone and reduced resistance within the local vasculature.

Dosage and Administration Information

How to Use Alprostadil

Alprostadil's administration is governed by the specific preparation and therapeutic context, necessitating distinct routes and dosing regimens.

Administration Scope

Feature	Detail
Route of administration	Intracavernosal injection (for use in adult males); Intraurethral administration (transurethral pellet); Intravenous infusion (for use in neonates).
Dosing schedule	Intracavernosal: Initial dose titration starts at 2.5 mu g or 1.25 mu g depending on etiology, with doses not recommended to exceed 60 mu g. Neonatal IV: Initial continuous infusion is typically 0.05 to 0.1 mu g/ kg/ min.
Timing in relation to meals	Not applicable; administration is independent of food intake.
Preparation requirements	The lyophilized powder for injection must be reconstituted immediately before use with the specified diluent.
Age-group administration rules	The intravenous infusion route is specifically authorized for neonates for certain heart conditions; other forms are for adult males only.
Missed-dose rules	Not specified, as use is either as-needed or continuous infusion.
Special procedural conditions	The initial intracavernosal injection and dose titration must be performed in the health care provider’s office, and the patient must remain until complete detumescence occurs.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Injection, Intraurethral, and Infusion.
Frequency pattern	Intermittent, as-needed. Maximum frequency for injection is no more than 3 times weekly, with at least a 24-hour interval between administrations.

Resulting Procedural Structure

Official step sequence:

The prescribed powder for injection must first be reconstituted with the provided diluent immediately before administration.
The first dose is always administered under the direct supervision of a health care provider to determine the lowest effective maintenance dose.
Once established, the maintenance dose must be used on an as-needed basis and strictly comply with the maximum frequency of three times per week.

Connection to the overall use protocol (3 sentences): The protocol dictates a rigorous, medically supervised approach for establishing the correct individualized dose, followed by a constrained intermittent self-administration schedule for one indication. For the neonatal use, administration demands continuous intravenous infusion and specialized monitoring due to the drug’s rapid metabolism and the critical nature of the application. These instructions define the required preparation steps, dosing limits, and required settings for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alprostadil

Evidence for Use in Erectile Dysfunction (ED)

Research exploring Alprostadil for erectile dysfunction has primarily included short-term, randomized controlled trials (RCTs) where the drug was evaluated in comparison to a non-active placebo, complemented by systematic reviews. These studies were used in research exploring how symptoms change over defined time intervals. The trials consistently monitored standardized functional scores, such as the International Index of Erectile Function (IIEF) score, and assessed outcomes reflecting daily functioning, specifically the successful completion of sexual activity.

For the intracavernosal form, studies examined functional outcomes captured through standardized instruments, such as the IIEF, during the defined observation period. Studies using the intraurethral and topical applications described findings with variability in the measured outcomes, and systematic reviews have noted that evidence quality varies across these latter studies. Research has also explored the use of Alprostadil in populations with conditions marked by functional limitations, including men with ED associated with diabetes or following prostate surgery.

Evidence for Use in Neonatal Heart Conditions

Alprostadil was studied for use in conditions associated with acute or disruptive episodes in newborn infants with ductal-dependent congenital heart defects. Clinical evidence for this palliative use stems mainly from initial observations and subsequent observational studies, rather than from traditional RCTs, as ethical concerns generally prohibit randomized placebo-controlled trials in this life-threatening setting. Research primarily examined and monitored temporary physiological imbalance, assessing outcomes monitoring physiological strain or stress, such as maintenance of the ductus arteriosus and changes in systemic blood pressure.

Studies conducted during periods of increased symptom activity in neonates documented measurements of systemic pressure changes and maintenance of the ductal structure in the acute, critical care setting. This evidence contributes to the body of evidence regarding the drug's role in this acute care setting. Research has also explored how different dosing strategies affect clinical parameters in this fragile population.

What is Still Uncertain About Alprostadil Research

A primary research limitation is that patient drop-out rates were high in the trials for erectile dysfunction. This means information regarding the full spectrum of patient experience over extended periods remains limited. For the intraurethral and topical formulations, evidence quality varies across studies, and findings were mixed in some meta-analyses.

Regarding neonatal care, research is still exploring short-term changes, but there is limited information for long-term outcomes and an acknowledged absence of consensus on the ideal dosing regimen for all neonates.

Key Studies & References

Efficacy and safety of transurethral alprostadil in the treatment of erectile dysfunction: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Alprostadil (FAQ)

Q: Why is Alprostadil sometimes prescribed when oral ED medicines do not work?

Official prescribing information describes Alprostadil as a vasodilator that acts directly to open blood vessels in the localized area of administration. This direct mechanism of action is different from that of oral treatments. For this reason, it is sometimes used when patients have not had a satisfactory response to oral erectile dysfunction medicines.

Q: Does Alprostadil work for all causes of erectile dysfunction?

Official documents indicate that Alprostadil is specified for the treatment of erectile dysfunction that results from certain types of underlying issues. These include neurogenic (nerve-related), vasculogenic (blood flow-related), psychogenic (psychological), or mixed causes.

Q: What happens to Alprostadil in the body after it is used?

Regulatory documents explain that the active compound is metabolized rapidly and extensively in the body following administration. This process occurs primarily in the lungs. The resulting inactive byproducts are then excreted mainly through the urine.

Q: How quickly does Alprostadil typically begin to work after administration?

The time it takes for the effect to begin differs based on the form used. According to official product information, an erection may occur within 5 to 20 minutes after injection. The intraurethral pellet form typically begins to work in 5 to 10 minutes.

Q: What is the typical duration of the effect after Alprostadil is administered?

The intended duration of the erection is generally described in official sources as lasting approximately 30 to 60 minutes. This timeframe is consistent with the goal of supporting sexual activity.

Q: Is it true that the effect should not last longer than one hour?

Yes, the intended duration of the resulting erection is generally described as being less than or equal to one hour. Official documents state that medical assistance should be sought immediately for any erection that persists for longer than four hours, as this is a serious adverse reaction called priapism.

Q: Can the onset of action be different depending on the form of Alprostadil used?

Yes, official regulatory information indicates that the time to onset is different depending on the route of administration. For instance, an erection may be experienced within 5 to 10 minutes after using the intraurethral pellet, compared to 5 to 20 minutes for the injectable form.

Q: Are there any serious side effects that require immediate medical attention?

Regulatory documents emphasize that a prolonged erection lasting four hours or more (priapism) is a potentially serious adverse reaction. Regulatory documents note that immediate medical assistance should be sought if this occurs. This warning highlights the importance of timely intervention for this rare but serious risk.

Q: What are the reported side effects for a female partner exposed to the medication?

For the intraurethral form, the side effect of vulvovaginal pruritus, or itching, has been reported in female partners. Additionally, official warnings include a statement regarding the use of a barrier method during intercourse if the partner is pregnant or may become pregnant to prevent possible fetal exposure.

Q: What is the risk level of a prolonged erection lasting more than four hours?

Clinical trial data cited in official documents provide specific figures regarding this risk. For one injectable product, the incidence of priapism (an erection lasting more than six hours) was reported as 0.4%. A prolonged erection lasting four hours or more was reported in 4% of patients in one trial.

Q: Is a temporary burning sensation considered a normal expected effect?

Yes, a warmth or burning sensation is listed in official product information as a commonly reported side effect. This is particularly noted in patients using the intraurethral suppository form of the medicine.

Q: What are the key differences between the injection and the suppository forms of Alprostadil?

The two forms differ primarily in their administration method and the way they are absorbed. Official information also notes differences in their typical time to onset and their reported local side effect profiles, specifically the frequency of pain and burning sensation.

Q: Why do some individuals choose Alprostadil over oral ED tablets?

Individuals may choose this medication if oral ED treatments have not resulted in a satisfactory response, as it is described as a next-step therapy. Official information describes Alprostadil’s action as direct and local, which can provide an alternative approach compared to systemic oral pills.

Q: Is there a difference in effectiveness between the injection and suppository forms?

Studies reviewed in official sources generally indicate a difference in effectiveness between the two local forms. Clinical studies referenced in official sources generally report higher successful intercourse rates for the injectable form compared to the suppository form.

Q: Why is topical Alprostadil cream not commonly available in all regions?

Regulatory documents note that the topical cream formulation does not have approval from all major regulatory bodies. For example, the product is not approved by the U.S. Food and Drug Administration (FDA), which affects its commercial availability and distribution in some regions.

Q: Does Alprostadil offer any protection against sexually transmitted infections (STIs)?

Official warnings clearly state that this medicine does not prevent pregnancy. Furthermore, it does not offer protection against infections that are spread through sexual contact, such as HIV or hepatitis.

Q: Is Alprostadil sometimes used by doctors for diagnostic purposes in ED evaluation?

Yes, the injectable form is indicated for use as an adjunct to other diagnostic tests. Official documents specify its role in combination with procedures like duplex or Doppler ultrasound in the comprehensive diagnosis of erectile dysfunction.

Q: What is the general advice regarding storage for the injectable form of Alprostadil (reconstituted solution)?

The official product labeling provides specific storage requirements for the prepared medicine. The reconstituted solution is required to be used within 24 hours and stored at or below 25 C (77 F).

How should Alprostadil be stored and disposed of?

Storage and Disposal of Alprostadil

Official storage conditions are specific to the product type and strength. Alprostadil for injection (20 mcg) requires storage at controlled room temperature (20 C to 25 C), while the urethral suppository (MUSE) and the 40 mcg injection vial (prior to dispensing) require refrigeration (2 C to 8 C). The injection powder must not be allowed to freeze, and the reconstituted solution must not be refrigerated, requiring use within 24 hours.

Storage Restriction	Requirement
Temperature	Product-specific: Refrigeration or 20 C to 25 C
Freezing	Must not be allowed to freeze
Reconstituted Solution	Use within 24 hours; do not refrigerate
Child Protection	Keep out of the reach and sight of children

Used needles and syringes must be immediately placed in an FDA-cleared sharps disposal container. They must not be thrown into household trash or flushed down the toilet.

Alprostadil